Cwm, LLC Cytokinetics Inc Transaction History

Cwm, LLC

$24.1 Billion
Q4 2024

A detailed history of Cwm, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Cwm, LLC holds 979 shares of CYTK stock, worth $41,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares

979

Previous 230 325.65%

Holding current value

$41,862

Previous $12,000 283.33%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$46.36 - $58.62 $34,723 - $43,906	749 Added 325.65%	979 $46,000
Q3 2024 Oct 08, 2024	BUY	$51.22 - $60.16 $2,612 - $3,068	51 Added 28.49%	230 $12,000
Q2 2024 Jul 09, 2024	SELL	$47.86 - $75.05 $2,967 - $4,653	-62 Reduced 25.73%	179 $10,000
Q1 2024 Apr 05, 2024	SELL	$63.75 - $108.06 $9,180 - $15,560	-144 Reduced 37.4%	241 $17,000
Q4 2023 Feb 01, 2024	SELL	$26.88 - $83.49 $833 - $2,588	-31 Reduced 7.45%	385 $32,000
Q3 2023 Oct 11, 2023	SELL	$29.46 - $36.61 $1,473 - $1,830	-50 Reduced 10.73%	416 $12,000
Q2 2023 Aug 03, 2023	SELL	$32.62 - $40.75 $260 - $326	-8 Reduced 1.69%	466 $15,000
Q1 2023 Apr 28, 2023	BUY	$33.36 - $45.71 $800 - $1,097	24 Added 5.33%	474 $17,000
Q4 2022 Feb 01, 2023	SELL	$35.77 - $51.11 $3,147 - $4,497	-88 Reduced 16.36%	450 $21,000
Q3 2022 Oct 27, 2022	BUY	$38.54 - $54.52 $9,442 - $13,357	245 Added 83.62%	538 $26,000
Q2 2022 Jul 28, 2022	SELL	$33.93 - $48.92 $1,323 - $1,907	-39 Reduced 11.75%	293 $12,000
Q1 2022 Apr 21, 2022	BUY	$29.74 - $46.0 $118 - $184	4 Added 1.22%	332 $12,000
Q4 2021 Jan 31, 2022	SELL	$34.35 - $46.38 $19,648 - $26,529	-572 Reduced 63.56%	328 $15,000
Q2 2020 Jul 22, 2020	BUY	$11.15 - $24.64 $10,035 - $22,176	900 New	900 $21,000

Others Institutions Holding CYTK

# of Institutions

407

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.42M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.03B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account